Thursday 8th September 2022 |
Text too small? |
Cannasouth Limited (NZX: CBD ) has received clarification during recent discussions with the Medicinal Cannabis Agency related to technical aspects associated with achieving the New Zealand Minimum Quality Standard for cannabis flower as a finished product. The insights gained have helped Cannasouth optimise post-harvest processes which will ultimately lead to a higher quality finished product.
The adopted process improvements remove complexity and streamline our operations, however require additional data to validate the changes. This data will be gathered during our upcoming commercial harvest scheduled to commence on the 19th of September.
Validation is a key component of the Good Manufacturing Practices (GMP) accreditation process. Cannasouth has sought deferral of its GMP audit while the new data pack is assembled. Cannasouth is working with the regulators to arrange a new audit date at the earliest opportunity.
GMP covers the post-harvest, drying and packing processes and is required for higher value premium flower to be used as a finished product in most jurisdictions, including New Zealand. This is an important distinction from Good Agricultural Collection Practices (GACP) accreditation, which Cannasouth achieved in August 2022, which opens the pathway for the export of cannabis flower as a start material for further manufacture.
-ENDS-
NXZ MAP_CBD Regulatory Clarification and GMP Audit Timing
No comments yet
December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors